Crescom Launches Global Proof of Concept of Pediatric Musculoskeletal AI Tool

June 16, 2026  —  Crescom has officially launched a global clinical Proof of Concept (PoC) of its pediatric musculoskeletal AI solutions in collaboration with the Department of Radiology at Mass General Brigham (MGB).

This upcoming global clinical validation study will be directly conducted by the Department of Radiology at Massachusetts General Hospital. The collaboration carries significant weight, as Crescom's technology is now undergoing global clinical validation and utility studies at one of the world's foremost institutions in medical imaging.

The validation study covers three core solutions: 

• bone age analysis AI MediAI-BA (FDA 510(k) cleared) 

• full lower-limb length measurement AI MediAI-SG 

• scoliosis severity auto-measurement AI MediAI-SC.

Mass General Brigham radiologists will compare AI-generated readings against expert clinical interpretations, conducting a comprehensive assessment of both clinical validity and real-world usability, while collecting user feedback from the U.S. clinical environment to refine the solutions and establish a foundation for local commercialization.

Pediatric Imaging Continues to Grow

While the number of pediatric imaging specialists remains extremely limited, the volume of related imaging studies continues to grow steadily. Consequently, clinical fields are showing rapidly increasing interest in optimizing operational workflows through AI-driven automated analysis. Through this clinical validation study with Mass General Brigham, Crescom plans to objectively demonstrate, utilizing data from a world-renowned institution, that its musculoskeletal AI technology can substantively improve the reading efficiency of medical specialists.

This collaboration with Mass General Brigham is expected to serve as a pivotal milestone for Crescom to establish a robust clinical track record in the North American radiology and pediatric growth clinic markets, while expanding its network with key local healthcare institutions. Furthermore, the company plans to integrate its pediatric musculoskeletal analysis and growth prediction solutions with the North American youth athletic development industry, where substantial potential demand is anticipated.

The study is also supported by the Ministry of Health and Welfare of the Republic of Korea.